华润医药：华润博雅生物预期年度归母净利润1.05亿元至1.365亿元 同比大幅下降

Core Viewpoint - China Resources Biopharma (华润医药) announced a significant decline in the net profit of its subsidiary, China Resources Boya Biopharma (华润博雅生物), for the fiscal year ending December 31, 2025, primarily due to market challenges and the impact of acquisitions [1][2] Group 1: Financial Performance - The net profit attributable to shareholders of China Resources Boya Biopharma is expected to be approximately RMB 105 million to RMB 136.5 million, a substantial decrease from RMB 397 million in the previous year [1] - The expected net loss, after excluding non-recurring items, is projected to be between RMB 7.5 million and RMB 15 million, compared to a net profit of RMB 302 million in the prior year [1] - The anticipated impact of non-recurring items on net profit is about RMB 120 million, influenced by government subsidies, asset sales, and wealth management income [2] Group 2: Business Challenges - The decline in net profit is largely attributed to a downturn in the market for hyaluronic acid products distributed by Anhui Greenke Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Green Cross Hong Kong Holdings, which was acquired in November 2024 [2] - The acquisition of Green Cross Hong Kong Holdings has led to impairment losses on intangible assets and goodwill totaling approximately RMB 300 million [2] - The blood products business of China Resources Boya Biopharma has faced challenges due to expanded centralized procurement, DRG/DIP reforms, medical insurance cost controls, and increased regulatory scrutiny, resulting in reduced clinical prescriptions and demand [2] Group 3: Strategic Initiatives - China Resources Boya Biopharma is committed to implementing the "1246" model and is focusing on "four remolds" (value remolding, business remolding, organizational remolding, and spiritual remolding) to navigate the complex market environment [1] - The company anticipates a year-on-year increase in operating revenue of 10% to 25%, primarily driven by the acquisition of Green Cross Hong Kong Holdings [1]